Indian generic drugmakers set to score from MPP deals on HIV drugs
Seven new sub-licensing agreements for the manufacture of generic HIV medicines and two new generation drugs, atazanavir and dolutegravir, by the Medicines Patent Pool (MPP), is set to usher in a new era of innovative production, reports The Pharma Letter's India correspondent.
A shot in the arm for generic drug majors, the MPP, a United Nations backed organization, entered into an initial agreement with Chinese manufacturer Desano, as well as with India based Cipla, Mylan’s Indian subsidiary, and Micro Labs.
The MPP has also extended collaborations with three other Indian firms: Aurobindo, Laurus Labs - a Hyderabad based manufacturer of active pharmaceutical ingredients (APIs), and Pune-based Emcure, for the manufacture of the generic HIV drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze